Co-treatment of Colchicine and Rosiglitazone synergistically inhibits cytokine-driven inflammation and modulates the related hsa-miRNA26a-5p, hsa-miRNA21-5p, and STAT3 expression in non-small cell lung cancer. - Younes N; Sadek O; Sultan A (Naunyn-Schmiedeberg's archives of pharmacology, 2026)